TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M

TELA Bio, Inc.

2025-Q1 EPS reported -$0.25 revenue$18,520,000

Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.
Net loss $11.3M vs $5.7M; operating loss $10.5M (prior-year included $7.6M asset sale gain).
Cash $42.8M; reiterates FY2025 revenue guidance $85-88M (23-27% growth), opEx flat YoY.
Full U.S. launch of larger OviTex PRS for plastic/reconstructive surgery commenced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.